Description

EB1002 is a potent, selective agonist of the NK2R, engineered for extended activity and high stability. In dietary-induced obesity (DIO) animal models, it effectively reduces adiposity by suppressing appetite, increasing energy expenditure, and improving insulin sensitivity and mitochondrial function—without compromising lean muscle mass. Its benefits are independent of leptin signaling and involve both central and peripheral pathways, showing efficacy even in diabetic and leptin-deficient models.

Product Specifications

Mechanism of Action & Research Applications

EB1002 targets the NK2 receptor, enabling dual modulation of appetite (central) and energy expenditure (peripheral). Benefits include:

• Significant fat loss with preserved lean mass

• Enhanced insulin sensitivity

• Elevated expression of mitochondrial biogenesis markers like PGC-1?

• Improved metabolic outcomes in leptin-deficient and diabetic animal models

These properties make EB1002 a powerful tool in obesity, diabetes, and energy metabolism research.

Side Effects (For Research Context Only)

In controlled studies, EB1002 may cause:

• Temporary gastrointestinal effects (e.g., changes in stool frequency) at high doses

• No significant liver toxicity or histopathological markers observed in dose-escalation safety assessments

Disclaimer

EB1002 is strictly for laboratory research use only. It is not approved for clinical, therapeutic, or diagnostic applications.